Boehringer Ingelheim, Lifebit partner on AI for infectious disease outbreaks

By The Science Advisory Board staff writers

June 9, 2021 -- Boehringer Ingelheim has established a long-term partnership with Lifebit Biotech to utilize natural language processing and artificial intelligence (AI) for the detection and early reporting of global disease outbreaks.

The collaboration aims at using real-world data collected from scientific publications and other open sources to provide insights into the latest infectious disease outbreaks. Using Lifebit's real-world evidence analysis system, REAL platform, will help Boehringer Ingelheim prioritize its research and development efforts.

As part of the partnership, researchers from both organizations will work together to combine real-world evidence and AI algorithms to identify infectious disease outbreaks and respond accordingly. Lifebit will use REAL's advanced analytic capabilities to automatically notify users of relevant outbreaks, such as transboundary disease spread or the emergence of novel pathogens like COVID-19. The system is built on an active learning architecture, meaning that as more relevant data are ingested, the accuracy of the system will increase.

Financial details of the partnership were not disclosed.

Boehringer Ingelheim to advance Dicerna RNAi candidate
Boehringer Ingelheim has accepted Dicerna Pharmaceuticals GalXC RNA interference (RNAi) candidate for its development for the treatment of chronic liver...
Oxford Biomedica to manufacture vectors for Boehringer Ingelheim
Oxford Biomedica has signed a three-year deal to manufacture and supply various types of viral vectors to Boehringer Ingelheim.
Boehringer Ingelheim, Cure Genetics to develop novel AAV
Cure Genetics will collaborate with Boehringer Ingelheim to develop novel adeno-associated virus (AAV) vectors leveraging Cure Genetics' proprietary Velp...
Boehringer Ingelheim expands COVID-19 collaborations
Boehringer Ingelheim announced that it is significantly increasing support for the fight against COVID-19, particularly by adding a number of strategic...

Copyright © 2021 scienceboard.net


Conferences
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter